The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895
Current Oncology · 2023
DOI: 10.3390/curroncol30050380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Maureen Trudeau und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
CADTH read with interest the commentary published on 16 December 2022, entitled “Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain” [...]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
- CADTH, Ottawa, ON K1S 5S8, Canada.
Zitieren
APA
Trudeau, M., & Fraser, B. (2023). The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895. Current Oncology. https://doi.org/10.3390/curroncol30050380
Vancouver
Trudeau M, Fraser B. The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895. Current Oncology. 2023. doi:10.3390/curroncol30050380
BibTeX
@article{Trudeau2023,
author = {Trudeau, Maureen and Fraser, Brent},
title = {The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30050380}
}
EUVIMED